NIH-funded research NIH-funded research

How cannabis legalization affects mental health and substance use in people with psychosis

Official title: Impact of cannabis legalization and commercialization on substance use and mental health outcomes in psychosis

Funded at Cambridge Health Alliance · NIH-11032923 · Data updated 2026-11-12

This study looks at how the legalization and sale of cannabis affects people with psychotic disorders, especially in terms of their substance use and mental health, to help understand any risks they might face.

More Mental Health research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionCambridge Health Alliance
NIH-funded
Lab location1 site (Cambridge, United States)
Project startDecember 15, 2024
Project endNovember 30, 2028
Funding year2025
Award (this year)$177,110
NIH project number1K23DA062173-01
Project IDNIH-11032923 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals aged 21 and older who have been diagnosed with psychotic disorders, such as schizophrenia.

Less likely to help

Patients who do not have a history of psychosis or are under the age of 21 may not receive direct benefits from this research.

What this research studies

This research investigates the impact of cannabis legalization and commercialization on individuals with psychotic disorders, particularly focusing on how these changes affect their substance use and mental health outcomes. The study will analyze existing data from national surveys and specialized clinics to understand the relationship between cannabis market expansion and the health of those with serious mental illnesses. By employing advanced statistical methods, the research aims to identify potential risks associated with cannabis use in this vulnerable population.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding and management of cannabis-related risks for individuals with psychosis.

How similar studies have gone: Previous research has indicated that cannabis use can exacerbate symptoms in individuals with psychosis, suggesting that this study's focus on commercialization effects is both relevant and necessary.

Where this research is happening

  • Cambridge Health Alliance
    Cambridge, United States
    Active

Researchers

  • Principal investigator: Hyatt, Andrew — Cambridge Health Alliance
  • Study coordinator: Hyatt, Andrew

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.